In-licensing of compounds between OrganoTherapeutics and the LDC
- OrganoTherapeutics and the Lead Discovery Center GmbH (LDC) worked together on the discovery of LRRK2 GTPase inhibitor drugs.
- The project led to 278 identified hit compounds.
- This collaboration led to the in-licensing of compound set, opening the door to further drug development in the LRRK2 field.
Mutations in the LRRK2 gene have been identified in patients suffering from familial and sporadic Parkinson’s Disease. The LRRK2 protein is often implicated in the disease progression, being therefore a potential therapeutic target for treatments. The Lead Discovery Center in Dortmund and OrganoTherapeutics have worked on the screening of 140.000 molecules, resulting in 278 hit compounds for the GTPase inhibition in LRRK2. This opens the door to further screening and in vitro validation, with the goal of obtaining safe and effective therapeutics that could rescue neurodegeneration in Parkinson’s Disease. OrganoTherapeutics celebrates this advance that brings them one step forward to developing efficient therapeutics not only to ameliorate Parkinson’s Disease symptoms, but to break the disease progression.
OrganoTherapeutics CEO, Jens Schwamborn mentions “XXX”.
About the Lead Discovery Center:
The Lead Discovery Center GmbH is a translational drug discovery organization that collaborates with both academia and industry. They work together with their collaborating partners on projects that lead to commercially viable compounds. With more than 100 publications and patents and 120 drug discovery projects started since 2008, 15 successfully completed projects have led to partnerships or licensing to industry collaborators.
For more information visit: www.lead-discovery.de
About OrganoTherapeutics:
OrganoTherapeutics is a spin-off biotech company from the University of Luxembourg and the Luxembourg center for Systems Biomedicine. Founded in 2019, they use proprietary human-specific midbrain organoids for drug discovery, screening and development in the context of neurodegeneration and Parkinson’s Disease. OrganoTherapeutics’ approach is focused on AI analysis of Parkinson’s Disease phenotypes and phenotype-based drug screening. They establish international partnerships and collaborations with pharmaceutical and biotech companies.